TY - JOUR
T1 - Development and evaluation of an accelerometer-based protocol for measuring physical activity levels in cancer survivors
T2 - Development and usability study
AU - Crane, Tracy E.
AU - Skiba, Meghan B.
AU - Miller, Austin
AU - Garcia, David O.
AU - Thomson, Cynthia A.
N1 - Funding Information: The authors wish to thank all the work and efforts of the staff and the undergraduate and graduate student research team who worked on this project from its inception: Natasha Burrell, Kelly Carroll, Sarah Lavelle, Sophia Perkin, Jennifer Shipley, McKenna Scheldt, Madeline Schneider, Patrice Tillman, Amanda Younger, and Samantha Werts. We also thank the 580 ovarian cancer survivors who dedicated their time and provided data for this research. This work was supported by the National Cancer Institute grants to NRG Oncology (U10 CA 180822), NRG operations (U10 CA180868), and UG1CA189867 (NCORP). Additional funding for this research was provided by the NRG Grant (R305B160003), the National Institutes of Health National Cancer Institute (1R01 CA186700), the BMISR at the UACC Support Grant (P30 CA023074), and the West Valley Ovarian Cancer Alliance. Publisher Copyright: © Tracy E Crane, Meghan B Skiba, Austin Miller, David O Garcia, Cynthia A Thomson. Originally published in JMIR mHealth and uHealth (http://mhealth.jmir.org), 24.09.2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR mHealth and uHealth, is properly cited. The complete bibliographic information, a link to the original publication on http://mhealth.jmir.org/, as well as this copyright and license information must be included.
PY - 2020/9
Y1 - 2020/9
N2 - Background: The collection of self-reported physical activity using validated questionnaires has known bias and measurement error. Objective: Accelerometry, an objective measure of daily activity, increases the rigor and accuracy of physical activity measurements. Here, we describe the methodology and related protocols for accelerometry data collection and quality assurance using the Actigraph GT9X accelerometer data collection in a convenience sample of ovarian cancer survivors enrolled in GOG/NRG 0225, a 24-month randomized controlled trial of diet and physical activity intervention versus attention control. Methods: From July 2015 to December 2019, accelerometers were mailed on 1337 separate occasions to 580 study participants to wear at 4 time points (baseline, 6, 12, and 24 months) for 7 consecutive days. Study staff contacted participants via telephone to confirm their availability to wear the accelerometers and reviewed instructions and procedures regarding the return of the accelerometers and assisted with any technology concerns. Results: We evaluated factors associated with wear compliance, including activity tracking, use of a mobile app, and demographic characteristics with chi-square tests and logistic regression. Compliant data, defined as ≥4 consecutive days with ≥10 hours daily wear time, exceeded 90% at all study time points. Activity tracking, but no other characteristics, was significantly associated with compliant data at all time points (P<.001). This implementation of data collection through accelerometry provided highly compliant and usable activity data in women who recently completed treatment for ovarian cancer. Conclusions: The high compliance and data quality associated with this protocol suggest that it could be disseminated to support researchers who seek to collect robust objective activity data in cancer survivors residing in a wide geographic area.
AB - Background: The collection of self-reported physical activity using validated questionnaires has known bias and measurement error. Objective: Accelerometry, an objective measure of daily activity, increases the rigor and accuracy of physical activity measurements. Here, we describe the methodology and related protocols for accelerometry data collection and quality assurance using the Actigraph GT9X accelerometer data collection in a convenience sample of ovarian cancer survivors enrolled in GOG/NRG 0225, a 24-month randomized controlled trial of diet and physical activity intervention versus attention control. Methods: From July 2015 to December 2019, accelerometers were mailed on 1337 separate occasions to 580 study participants to wear at 4 time points (baseline, 6, 12, and 24 months) for 7 consecutive days. Study staff contacted participants via telephone to confirm their availability to wear the accelerometers and reviewed instructions and procedures regarding the return of the accelerometers and assisted with any technology concerns. Results: We evaluated factors associated with wear compliance, including activity tracking, use of a mobile app, and demographic characteristics with chi-square tests and logistic regression. Compliant data, defined as ≥4 consecutive days with ≥10 hours daily wear time, exceeded 90% at all study time points. Activity tracking, but no other characteristics, was significantly associated with compliant data at all time points (P<.001). This implementation of data collection through accelerometry provided highly compliant and usable activity data in women who recently completed treatment for ovarian cancer. Conclusions: The high compliance and data quality associated with this protocol suggest that it could be disseminated to support researchers who seek to collect robust objective activity data in cancer survivors residing in a wide geographic area.
KW - Activity trackers
KW - Cancer survivors
KW - Mobile phone
KW - Physical activity
KW - Wearable electronic devices
UR - http://www.scopus.com/inward/record.url?scp=85091640063&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091640063&partnerID=8YFLogxK
U2 - 10.2196/18491
DO - 10.2196/18491
M3 - Article
C2 - 32969828
SN - 2291-5222
VL - 8
JO - JMIR mHealth and uHealth
JF - JMIR mHealth and uHealth
IS - 9
M1 - e18491
ER -